Funded Biotechnology Startups
Across the 20 most recent biotechnology/pharmaceutical/healthcare rounds shown, Crystalys Therapeutics’ $205M on 2025-10-04 is the clear outlier; the next-…
Across the 20 most recent biotechnology/pharmaceutical/healthcare rounds shown, Crystalys Therapeutics’ $205M on 2025-10-04 is the clear outlier; the next-largest disclosed amounts cluster far lower at $120M (Solve Therapeutics, 2025-11-21), $96M (TORL BioTherapeutics, 2025-10-12), and $94M (Trogenix, 2025-10-11). The disclosed-dollar range also shows a floor: the smallest disclosed amount is $1M for Twinpig Biolab (2025-11-22), while several other companies have undisclosed amounts.
The funding activity concentrates in a tight late-2025 window: the newest round is Aerska on 2026-02-09, while the oldest entry shown is 2025-10-04. Stage classification is dominated by Series-labeled rounds and “Series Unknown”: 8 of 20 entries are “Series Unknown” and 3 of 20 list “undisclosed” amounts, with “Series A” appearing repeatedly (Aerska 2026-02-09; Waker Biology 2025-11-26; Kunshi Biotechnology 2025-11-20; Neok Bio 2025-11-09; Trogenix 2025-10-11; plus UniXell Biotechnology marked undisclosed on 2025-11-03). Geographically, the list is split between the US and China, with the US repeatedly represented (e.g., Solve Therapeutics 2025-11-21; Lifordi 2025-11-19; Neok Bio 2025-11-09; Trogenix 2025-10-11; Crystalys Therapeutics 2025-10-04).
Most recent rounds
20 shownRelated listings
Frequently asked
Which disclosed round is the dominant outlier in this list, and how do the next-largest disclosed amounts compare?
Crystalys Therapeutics’ disclosed $205M on 2025-10-04 is the highest amount shown. The next-largest disclosed amounts are notably lower: Solve Therapeutics at $120M (2025-11-21), TORL BioTherapeutics at $96M (2025-10-12), and Trogenix at $94M (2025-10-11).
Are any stages over-represented, and what share of entries avoid a specific stage label?
“Series A” is the most frequent labeled stage among the rows (Aerska 2026-02-09; Waker Biology 2025-11-26; Kunshi Biotechnology 2025-11-20; Neok Bio 2025-11-09; Trogenix 2025-10-11). In parallel, 8 of 20 entries are labeled “Venture - Series Unknown,” and 3 of 20 list “undisclosed” amounts.
Do the rounds cluster into a narrow date window, and what are the temporal edges of the data shown?
Yes. The newest entry is Aerska on 2026-02-09, while the oldest entry shown is Crystalys Therapeutics on 2025-10-04, spanning roughly three months. Many entries are concentrated in October–November 2025 (e.g., multiple rounds from 2025-11-19 to 2025-10-11).
Is the geography concentrated in a small set of cities or countries?
The list concentrates at the country level between the US and China rather than a single city cluster: US rounds include Solve Therapeutics (Belmont, 2025-11-21, $120M), Lifordi Immunotherapeutics (Burlington, 2025-11-19, $42M), and Crystalys Therapeutics (San Diego, 2025-10-04, $205M). China is repeatedly represented as well (e.g., Waker Biology in Minhang, $14M on 2025-11-26; Full-Life Technologies in Shanghai, $50M on 2025-10-05).
Which companies sit at the extreme low end of disclosed funding, and are they isolated or part of a broader pattern?
Twinpig Biolab’s $1M (2025-11-22) is the smallest disclosed amount in the list, with several other very low disclosed rounds nearby (e.g., BOOST Pharma $2M on 2025-10-31; Artizan Biosciences $2M on 2025-11-10). However, some entries’ amounts are “undisclosed” (e.g., Imbria Pharmaceuticals on 2025-11-19), which makes the low disclosed tail uneven rather than fully characterizing total funding behavior.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.